期刊
NEUROLOGICAL SCIENCES
卷 32, 期 2, 页码 351-358出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-010-0469-0
关键词
Multiple sclerosis; Natalizumab; PML; IRIS
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据